CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Reports

We found 7250 result(s)

Vedolizumab (Entyvio)

Last Updated: March 23, 2016
Result type: Reports
Product Line: Reimbursement Review
Generic Name: Vedolizumab
Indications: Crohn’s disease

  • Brand Name: Entyvio
  • Manufacturer: Takeda Canada Inc.
  • Project Number: SR0487-000
  • Project Status: Complete
  • Submission Type: Initial

The Canadian Medical Imaging Inventory, 2015

Last Updated:
Result type: Reports
opens in document viewer

CADTH updates the Canadian Medical Imaging Inventory every two years. For the latest version, visit www.cadth.ca/imaginginventory EXECUTIVE SUMMARY We conducted a survey of imaging providers in Canada so that we could provide an updated status of the holdings and use of specialist medical imaging in Canada. The Canadian Institute for Health In...

Mifepristone and misoprostol (Mifegymiso)

Last Updated: April 20, 2017
Result type: Reports
Product Line: Reimbursement Review
Generic Name: Mifepristone and misoprostol
Indications: Medical termination of pregnancy

  • Brand Name: Mifegymiso
  • Manufacturer: Celopharma Inc.
  • Project Number: SR0502-000
  • Project Status: Complete
  • Submission Type: Initial

CADTH Drug Portfolio Information Sessions — Agendas Now Available

Published on: October 14, 2016
Result type: News

The agendas are now available for the CADTH Drug Portfolio Information Sessions, which will be held on October 26, 2016, at the Allstream Centre in Toronto. The sessions are an opportunity for CADTH to engage with key stakeholders, provide program updates and other information, and hear directly about any issues and concerns. Full details and ...

Daclizumab beta (Zinbryta)

Last Updated: October 18, 2016
Result type: Reports
Product Line: Reimbursement Review
Generic Name: Daclizumab beta
Indications: Multiple Sclerosis, relapsing

  • Brand Name: Zinbryta
  • Manufacturer: Biogen Canada Inc.
  • Project Number: SR0508-000
  • Project Status: Complete
  • Submission Type: Initial

Treatments for Locally Advanced Oropharyngeal Cancer: A Systematic Review of Clinical Effectiveness and Cost-Effectiveness

Last Updated: October 20, 2016
Result type: Reports
Product Line: Rapid Response

CADTH is undertaking a project on treatments for locally advanced oropharyngeal cancer. Oropharyngeal cancer is a type of head and neck cancer that begins in the oropharynx; it is the 13th most common diagnosed cancer and the 15th most common cause of cancer death for adults in Canada. Primary surgical therapy with or without adjuvant radiati...

  • Project Number: RE0033-000

Advance Notice: Stakeholder Feedback on the Draft Guidelines for the Economic Evaluation of Health Technologies: Canada (4th Edition)

Published on: September 20, 2016
Result type: News

A draft version of the updated Guidelines for the Economic Evaluation of Health Technologies: Canada (4th Edition) will be available for stakeholder feedback from October 28 through November 25, 2016. As per standard CADTH procedure, an invitation for feedback will be posted on our website at www.cadth.ca/feedback, and announced through our Hea...

CADTH Lecture Series – The Emergence of Health Technology Optimization & Managed Exit

Event Date: October 27, 2016
Result type: Events

The CADTH Lecture Series provides prominent scholars and opinion leaders with a forum to discuss pressing issues facing health technology assessment (HTA) and health care today. Tom Noseworthy, MD
Professor, Health Policy and Management, Department of Community Health Sciences and O’Brien Institute for Public Health, Cumming School...